Angelini Ventures
Headquarter
Basel, Switzerland
Milestones
Founded: 2015
Invested: 2024
Founders / CEO
Marina Udier, CEO
Vertical
Biotech
Board Participation
Paolo di Giorgio, Board Member
Developer of an immunotherapy platform designed to develop engineered viral vector vaccines for the treatment of cancer. The company's platform utilizes a portfolio of engineered viral vectors optimized for the efficient expression of long strings of tumor neoantigens and comprises a toolkit for the induction of broad and potent antitumor T-cell responses, enabling patients to enhance cancer-specific cellular immunity.
Related news:
Nouscom Secures €75.8 Million Series C Investment Boost for Advancing Cancer Vaccine Development